Decheng Capital LLC
MENLO PARK, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$685.1M2026 Q3
Positions11
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.99.9%
What Changed This Quarter?
Top Holdings
CGON
CG Oncology
65.9%
NUVB
Nuvation Bio
21.2%
ACRS
Aclaris Therapeutics
3.1%
AARD
Aardvark Therapeutics
3.0%
UPB
Upstream Bio
2.1%
RCUS
Arcus Biosciences
1.6%
EQ
Equillium
1.1%
Lyell Immunop…
Lyell Immunopharma
1.0%
New / Increased
0 new · 0 increased
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.